Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease. Although late-stage kidney cancer generated ...

For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

Keytruda and Lenvima combination showed a 50.6% overall response rate and 82.3% disease control rate in advanced non-clear cell kidney cancer. The median progression-free survival was 17.9 months, ...

Simple blood markers may predict nivolumab outcomes in metastatic renal cell carcinoma. Learn how eosinophils could help ...

In patients with renal cell carcinoma, a phase 2 trial tested neoadjuvant stereotactic ablative radiation therapy to the inferior vena cava tumor thrombus before radical nephrectomy with thrombectomy.

Neighborhood-level social determinants of health were associated with varying cancer risks and greater mortality among kidney ...